JP4700001B2 - 蛍光偏極撮像方法 - Google Patents
蛍光偏極撮像方法 Download PDFInfo
- Publication number
- JP4700001B2 JP4700001B2 JP2006527087A JP2006527087A JP4700001B2 JP 4700001 B2 JP4700001 B2 JP 4700001B2 JP 2006527087 A JP2006527087 A JP 2006527087A JP 2006527087 A JP2006527087 A JP 2006527087A JP 4700001 B2 JP4700001 B2 JP 4700001B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorescence
- image
- polarization
- polarization direction
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003384 imaging method Methods 0.000 title claims description 44
- 238000002875 fluorescence polarization Methods 0.000 title claims description 37
- 230000010287 polarization Effects 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 42
- 239000002872 contrast media Substances 0.000 claims description 30
- 238000002073 fluorescence micrograph Methods 0.000 claims description 14
- 238000000198 fluorescence anisotropy Methods 0.000 claims description 13
- 230000008520 organization Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 description 114
- 210000001519 tissue Anatomy 0.000 description 82
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 27
- 239000000975 dye Substances 0.000 description 22
- 239000003504 photosensitizing agent Substances 0.000 description 22
- 229950003937 tolonium Drugs 0.000 description 22
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 20
- 229960000907 methylthioninium chloride Drugs 0.000 description 20
- 239000004098 Tetracycline Substances 0.000 description 18
- 150000004032 porphyrins Chemical class 0.000 description 18
- 235000019364 tetracycline Nutrition 0.000 description 18
- 206010004146 Basal cell carcinoma Diseases 0.000 description 17
- 229960002180 tetracycline Drugs 0.000 description 17
- 229930101283 tetracycline Natural products 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 230000005284 excitation Effects 0.000 description 13
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 229950003776 protoporphyrin Drugs 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 12
- 230000003902 lesion Effects 0.000 description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- -1 for example Chemical compound 0.000 description 9
- 238000002428 photodynamic therapy Methods 0.000 description 9
- 201000008261 skin carcinoma Diseases 0.000 description 9
- 208000000453 Skin Neoplasms Diseases 0.000 description 8
- 229910052751 metal Chemical group 0.000 description 8
- 239000002184 metal Chemical group 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 4
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 229930187593 rose bengal Natural products 0.000 description 4
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 4
- 229940081623 rose bengal Drugs 0.000 description 4
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- HHXVUGCSLBZDTM-UHFFFAOYSA-N (6'-acetyloxy-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 HHXVUGCSLBZDTM-UHFFFAOYSA-N 0.000 description 3
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 3
- XAEPFBXVLMACNN-UHFFFAOYSA-N 3-[10,15,20-tris(3-hydroxyphenyl)-21,24-dihydroporphyrin-5-yl]phenol Chemical compound OC1=CC=CC(C=2C=3C=CC(N=3)=C(C=3C=C(O)C=CC=3)C3=CC=C(N3)C(C=3C=C(O)C=CC=3)=C3C=CC(N3)=C(C=3C=C(O)C=CC=3)C=3C=CC=2N=3)=C1 XAEPFBXVLMACNN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000000185 Localized scleroderma Diseases 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000000701 chemical imaging Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 229960003569 hematoporphyrin Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002186 photoactivation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- LBGCRGLFTKVXDZ-UHFFFAOYSA-M ac1mc2aw Chemical compound [Al+3].[Cl-].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 LBGCRGLFTKVXDZ-UHFFFAOYSA-M 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000004035 chlorins Chemical class 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 150000004033 porphyrin derivatives Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NLDYACGHTUPAQU-UHFFFAOYSA-N tetracyanoethylene Chemical group N#CC(C#N)=C(C#N)C#N NLDYACGHTUPAQU-UHFFFAOYSA-N 0.000 description 2
- 239000011882 ultra-fine particle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- KHUFHLFHOQVFGB-UHFFFAOYSA-N 1-aminoanthracene-9,10-dione Chemical class O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N KHUFHLFHOQVFGB-UHFFFAOYSA-N 0.000 description 1
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- RHBJMYOTXIENOZ-UHFFFAOYSA-N 2-[10,15,20-tris(2-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical class Oc1ccccc1-c1c2ccc(n2)c(-c2ccccc2O)c2ccc([nH]2)c(-c2ccccc2O)c2ccc(n2)c(-c2ccccc2O)c2ccc1[nH]2 RHBJMYOTXIENOZ-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- FNPOHMCPKIQLBU-UHFFFAOYSA-J 3-[20-(carboxylatomethyl)-18-(dioxidomethylidene)-8-ethenyl-13-ethyl-3,7,12,17-tetramethyl-2,3-dihydroporphyrin-23-id-2-yl]propanoate;hydron;tin(4+) Chemical compound [H+].[Sn+4].C1=C([N-]2)C(CC)=C(C)C2=CC(C(=C2C)C=C)=NC2=CC(C(C2CCC([O-])=O)C)=NC2=C(CC([O-])=O)C2=NC1=C(C)C2=C([O-])[O-] FNPOHMCPKIQLBU-UHFFFAOYSA-J 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical class C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- KOILFZXZLGMKAP-UHFFFAOYSA-N C(#CC(=O)O)C(=O)O.C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N1)=C2)C=CC=C3 Chemical compound C(#CC(=O)O)C(=O)O.C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N1)=C2)C=CC=C3 KOILFZXZLGMKAP-UHFFFAOYSA-N 0.000 description 1
- CVNLNYIYNOSEIT-UHFFFAOYSA-N C1=CC=[O+]C=C1.[SeH2] Chemical compound C1=CC=[O+]C=C1.[SeH2] CVNLNYIYNOSEIT-UHFFFAOYSA-N 0.000 description 1
- JUDGRMABQJKRPW-XIADSQHASA-N CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C Chemical class CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C JUDGRMABQJKRPW-XIADSQHASA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 150000001787 chalcogens Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000002243 cyclohexanonyl group Chemical group *C1(*)C(=O)C(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical class COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002675 image-guided surgery Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- PSDMOPINLDTFSZ-UHFFFAOYSA-N lutetium(3+) Chemical compound [Lu+3] PSDMOPINLDTFSZ-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6445—Measuring fluorescence polarisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/0205—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows
- G01J3/0224—Optical elements not provided otherwise, e.g. optical manifolds, diffusers, windows using polarising or depolarising elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/10—Arrangements of light sources specially adapted for spectrometry or colorimetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
- G01J3/4406—Fluorescence spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J2003/1213—Filters in general, e.g. dichroic, band
- G01J2003/1217—Indexed discrete filters or choppers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
- G01N2021/6423—Spectral mapping, video display
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
エス・エル・ジャック(S.L. Jacques),ジェイ・アール・ロマン(J. R. Roman),ケイ・リー(K. Lee),「偏光による近表皮組織の撮像(Imaging superficial tissues with polarized light)」,Las. Surg. Med.,2000年,第26巻,p.119−129 エル・ブランカレオン(L. Brancaleon),エイ・ジェイ・ダーキン(A. J. Durkin),ジェイ・エイチ・トゥー(J. H. Tu),ジー・メネイカー(G. Menaker),ジェイ・ディー・ファロン(J. D. Fallon),エヌ・コリアンス(N. Kollians),「非メラノーマ性皮膚癌の生体内蛍光分光法(In vivo fluorescence spectroscopy of nonmelanoma skin cancer)」,Photochem. Photobiol.,2001年,第73巻,第2号,p.178−183 エイ・エム・ウエンバーグ(A. M. Wennberg),エフ・グドムンドソン(F. Gudmundson),ビー・ステンキスト(B. Stenquist),エイ・ターネステン(A. Ternesten),エル・メーレン(L. Moelrn),エイ・ローゼン(A. Rosen),オー・ラーコ(O. Larko),「撮像分光法を用いる基底細胞カルシノーマの生体内検出(In vivo detection of basal cell carcimoma using imaging spectroscopy)」,Acta Derm. Venereol.,1999年,第79巻,p.54−61 ジェイ・ヒューウエット(J. Hewett),ブイ・ネイドー(V. Nadeau),ジェイ・ファーガソン(J. Ferguson),エイチ・モーズリー(H. Moseley),エス・アイボットソン(S. Ibottoson),ジェイ・ダブリュー・アレン(J. W. Allen),ダブリュー・シベット(W. Sibbett),エム・パジェット(M. Padgett),「励起源が一体化された小型多重スペクトル撮像システムの近表皮癌の局所光力学的療法中の蛍光の生体内観察への適用(The application of a compact multispectral imaging system with integrated excitation source to in vivo monitoring of fluorescence during topical photodynamic therapy of superficial skin cancers)」,Photochem. Photobiol.,2001年,第73巻,第3号,p.278−282 エス・アンダーソン−エンゲルス(S. Andersson-Engels),ジー・キャンティ(G. Canti),アール・キュードゥ(R. Cueddu),シー・エカー(C. Eker),シー・アフ−クリンテベルグ(C. af Klinteberg),エイ・ピフェリ(A. Pifferi),ケイ・スヴァンベルグ(K. Svanberg),エス・スヴァンベルグ(S. Svanberg),ピー・タローニ(P. Taroni),ジー・バレンティニ(G. Valentini),アイ・ウオン(I. Wang),「皮膚の基底細胞カルシノーマの検出及び画定のための2つの蛍光撮像法の予備評価(Preliminary evaluation of two fluorescence imaging methods for the detection and delineation of basal cell carcinomas of the skin)」,Las. Surg. Med.,2000年,第26巻,p.76−82 ジェイ・エル・ウエスト(J. L. West)及びエヌ・ジェイ・ハラス(N. J. Halas),「ナノテクノロジーのバイオテクノロジーへの適用−個人的見解(Application of Nanotechnology to Biotechnology - Commentary)」,Current Opinion in Biotechnology,2000年,第11巻,p.215−220 ジェイ・イー・ブガイ(J. E. Bugaj),エス・アキレフ(S. Achilefu),アール・ビー・ドルショー(R. B. Dorshow),アール・ラジャゴパラン(R. Rajagopalan),「レセプタ標的造影剤−ペプチド共役プラットフォームに基づく生体内腫瘍の光学撮像のための新規な蛍光性造影剤(Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted contrast agent-peptide conjugate platform)」,J. Biomed. Opt.,2001年、第6巻,p.122−133 エイ・ブイ・カイサリー(A V. Kaisary),「生体内メチレンブルー染色法を用いる侵襲性膀胱カルシノーマにおける放射線治療の評価(Assessment of radiotherapy in invasive bladder carcinomas using in vivo methylene blue staining technique)」,Urology,1986年,第28巻,第2号,p.100−102 ジー・エム・アイゼン(G. M. Eisen),イー・エイ・モンゴメリー(E. A. Montgomery),エヌ・アズミ(N. Azumi),ディー−ピー・ハットマン(D-P. Hatmann),ピー・バーガバ(P. Bhargava),エム・リップマン(M. Loppman),エス・ビー・ベンジャミン(S. B. Benjamin),「バレット氏化生の定性的マッピング:介入試行のための前提条件(Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials)」,Gastrointestinal Endoscopy,1999年,第50巻,第6号,p.814−818 エイ・アール・オセロフ(A. R. Oseroff),ディー・オフオハ(D. Ohuoha),ジー・アラ(G. Ara),ディー・マコーリッフェ(D. McAuliffe),ジェイ・フォリー(J. Foley),エル・チンコッタ(L. Cincotta),「ミトコンドリア内造影剤がカルシノーマ細胞の選択的生体外光分解を可能にする(Intramitochondrial contrast agents allow selective in vitro photolysis of carcinoma cells)」,Proc. Natl. Acad. Sci. USA.,1986年,第83巻,p.9729−9733 ジェイ・アール・レイコビック(J. R. Lakowic)著,「蛍光顕微鏡検査法の原理(Principles of Fluorescence Spectroscopy)」,(米国ニューヨーク),プレナム・プレス(Plenum Press),1983年 ピー・ピー・フェオフィロフ(P. P. Feofilov),Izv. Akad. Nauk SSSR. Ser. Fiz.,1945年,第9巻,p.317 アール・エフ・チェン(R. F. Chen)及びアール・エル・ボウマン(R. L. Bowman),1965年
これまで本発明の好ましい実施形態及びそれらの改変形態を詳細に説明したが、本発明がこれらの実施形態及び改変形態に限定されず、添付される特許請求の範囲に定められる本発明の精神及び範囲を逸脱することなく当業者によってその他の改変及び変形が実施され得ることは当然である。
通常の顕微鏡による撮像の前に組織試料を染色するために多数の染色剤及び染料が病理学で用いられる。いくつかの染色剤は無毒であり、生体内で癌腫瘍に優先的に結合する。これらの発色団は生体染色剤と呼ばれ、本発明に関して特に注目され、有用である。特に、非局在化陽イオン電荷をもつ染料または染色剤は腫瘍において選択的な結合及び保持が可能である。これらには、ローダミン123のようなローダミン、フェノチアジニウム染料、メチレンブルー及びトルイジンブルーがある。生体内でコラーゲンに結合する赤−ピンク染色剤である、ローズベンガル及びエオシンのようなその他の生体染色剤を用いることができる。
Photofrin(登録商標)RTM(ポルフィマーナトリウム)、ヘマトポルフィリンIX、ヘマトポルフィリンエステル、ジヘマトポルフィリンエステル、合成ジポルフィリン、O-置換テトラフェニルポルフィリン(ピケットフェンスポルフィリン)、3,1-メソテトラキス(o-プロピナミドフェニル)ポルフィリン、ヒドロポルフィリン、ベンゾポルフィリン誘導体、ベンゾポルフィリン一酸誘導体(BPD-MA)、一酸環“a”誘導体、ベンゾポルフィリンのテトラシアノエチレン付加体、ベンゾポルフィリンのジメチルアセチレンジカルボキシレート付加体、内因性代謝前駆体、δ-アミノレブリン酸、ベンゾナフトポルフィラジン、自然生成ポルフィリン、ALA-誘導プロトポルフィリンIX、合成ジクロリン、テトラ(ヒドロキシフェニル)ポルフィリンシリーズのバクテリオクロリン、プルプリン、オクタエチルプルプリンのスズ及び亜鉛誘導体、エチオプルプリン、スズ-エチオプルプリン、ポルフィセン、クロリン、クロリンe6、クロリンe6のモノ-l-アスパチル誘導体、クロリンe6のジ-l-アスパチル誘導体、スズ(IV)クロリンe6、メタ-テトラヒドロキシフェニルクロリン、クロリンe6モノエチレンジアミンモノアミド、亜鉛メチルピロベルジン(ZNMPV)、コプロIIベルジントリメチルエステル(CVTME)及びジューテロベルジンメチルエステル(DVME)のような、ただしこれらには限定されない、ベルジン、フェオホルバイド誘導体、及びピロフェオホルバイド化合物、ランタナイドまたは金属置換または無置換テクサフィリン、ルテチウム(III)テクサフィリン、ガドリニウム(III)テクサフィリン。
メロシアニン、金属置換基の有無にかかわらないフタロシアニン、可変置換基の有無にかかわらないクロロアルミニウムフタロシアニン、スルホン化アルミニウムPC、環置換陽イオンPC、スルホン化AlPc、二スルホン化及び三スルホン化誘導体、スルホン化アルミニウムナフタロシアニン、金属置換基の有無にかかわらない及び可変置換基の有無に拘わらないナフタロシアニン、テトラシアノエチレン付加体、ナイルブルー、クリスタルバイオレット、アズールβクロライド、ローズベンガル、ベンゾフェノチアジニウム化合物、メチレンブルーを含むフェノチアジン誘導体。
ディールス・アルダー付加体、ジメチルアセチレンジカルボキシレート付加体、アントラセンジオン、アントラピラゾール、アミノアントラキノン、フェノキサジン染料、陽イオン性のピリリウムセレン及びピリリウムテルルの誘導体のようなピリリウムカルコゲン染料、陽イオン性イミン塩、テトラサイクリン及び、エバンスブルー、コンゴレッド及びトリパンブルーのような陰イオン性染料。
発色団または光増感剤は必要に応じて目標成分に連結させることができる。好ましい実施形態において、目標成分は抗体である。抗体成分は腫瘍細胞の表面に存在するエピトープに特異的に結合することができる。「特異的結合」は、抗体が非癌細胞に選択的に結合しないか、または非癌細胞が抗体によって僅かにしか認識されないことを意味する。抗体には、完全自然抗体、二価抗体、キメラ抗体、Fab、Fab'、単鎖V領域フラグメント(scFv)及び融合ポリペプチドを含めることができる。抗体はモノクローナルであることが好ましい。本実施形態において、担体分子、例えば抗体は、腫瘍細胞または癌腫瘍のその他の成分への発色団の結合に対するさらなる特異性を与えた。
2 ランプ
3,11,14 レンズ
4 フィルタホイール
5 集束レンズ
6 光ガイド
7 拡散板
8 コリメータ
9,13 偏光子
10 生体組織
12 フィルタ
15 CCDカメラ
100 撮像装置
Claims (2)
- 組織領域を撮像する方法において、
波長及び第1の偏極方向を有する光を前記組織領域に放射する工程、
前記第1の偏極方向を有する前記組織領域から放射される蛍光及び前記第1の偏極方向に垂直な第2の偏極方向を有する前記組織領域から放射される光を検出する工程、
前記第1の偏極方向を有する前記検出された光及び前記第2の偏極方向を有する前記検出された光に基づいて背景蛍光偏極画像を形成する工程、
前記第1の偏極方向を有する、蛍光造影剤で染色された前記組織領域から放射される蛍光及び前記第1の偏極方向に垂直な第2の偏極方向を有する前記染色された組織領域から放射される光を検出する工程、
前記第1の偏極方向を有する前記検出された光及び前記第2の偏極方向を有する前記検出された光に基づいて総蛍光偏極画像を形成する工程、及び
前記背景蛍光偏極画像(内因性蛍光画像)及び前記総蛍光偏極画像に基づいて異方性の純蛍光偏極画像を形成する工程、
を有してなることを特徴とする方法。 - 組織領域を撮像する方法において、
波長及び第1の偏極方向を有する光を前記組織領域に放射する工程、
前記第1の偏極方向を有する前記組織領域から放射される蛍光及び前記第1の偏極方向に垂直な第2の偏極方向を有する前記組織領域から放射される光を検出する工程、
前記第1の偏極方向を有する前記検出された光及び前記第2の偏極方向を有する前記検出された光に基づいて背景蛍光異方性画像を形成する工程、
前記第1の偏極方向を有する、蛍光造影剤で染色された前記組織領域から放射される蛍光及び前記第1の偏極方向に垂直な第2の偏極方向を有する前記染色された組織領域から放射される光を検出する工程、
前記第1の偏極方向を有する前記検出された光及び前記第2の偏極方向を有する前記検出された光に基づいて総蛍光異方性画像を形成する工程、及び
前記背景蛍光異方性画像(内因性蛍光画像)及び前記総蛍光異方性画像に基づいて異方性の純蛍光異方性画像を形成する工程、
を有してなることを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50451303P | 2003-09-19 | 2003-09-19 | |
US60/504,513 | 2003-09-19 | ||
PCT/US2004/030623 WO2005027730A2 (en) | 2003-09-19 | 2004-09-20 | Fluorescence polarization imaging devices and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007511243A JP2007511243A (ja) | 2007-05-10 |
JP4700001B2 true JP4700001B2 (ja) | 2011-06-15 |
Family
ID=34375514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006527087A Expired - Fee Related JP4700001B2 (ja) | 2003-09-19 | 2004-09-20 | 蛍光偏極撮像方法 |
Country Status (7)
Country | Link |
---|---|
US (4) | US7289205B2 (ja) |
EP (1) | EP1670347A4 (ja) |
JP (1) | JP4700001B2 (ja) |
AU (1) | AU2004273992B2 (ja) |
CA (1) | CA2539184A1 (ja) |
IL (1) | IL174379A0 (ja) |
WO (1) | WO2005027730A2 (ja) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8406498B2 (en) | 1999-01-25 | 2013-03-26 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
US20060257884A1 (en) * | 2004-05-20 | 2006-11-16 | Amnis Corporation | Methods for preparing and analyzing cells having chromosomal abnormalities |
US8885913B2 (en) | 1999-01-25 | 2014-11-11 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
US7450229B2 (en) | 1999-01-25 | 2008-11-11 | Amnis Corporation | Methods for analyzing inter-cellular phenomena |
US8131053B2 (en) | 1999-01-25 | 2012-03-06 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
AU2002213157A1 (en) | 2000-10-12 | 2002-04-22 | Amnis Corporation | System and method for high numeric aperture imaging systems |
US8103080B2 (en) * | 2004-03-16 | 2012-01-24 | Amnis Corporation | Method for imaging and differential analysis of cells |
US8953866B2 (en) | 2004-03-16 | 2015-02-10 | Amnis Corporation | Method for imaging and differential analysis of cells |
EP1800124B1 (en) * | 2004-03-16 | 2011-12-21 | Amnis Corporation | Image based quantitation of molecular translocation |
JP5034032B2 (ja) * | 2004-09-29 | 2012-09-26 | Sbiファーマ株式会社 | 腫瘍診断剤 |
US7545969B2 (en) * | 2004-12-16 | 2009-06-09 | Alliant Techsystems Inc. | Method and system for wide-area ultraviolet detection of forensic evidence |
WO2007008472A2 (en) * | 2005-07-08 | 2007-01-18 | Colorado Seminary, Which Owns And Operates The University Of Denver | Photoinduced signal amplification through externally sensitized photofragmentation in masked photosensitizers |
US20070016173A1 (en) * | 2005-07-14 | 2007-01-18 | Michael Kreindel | Protective material, clothing item and method of protection |
EP1931263A2 (en) | 2005-08-29 | 2008-06-18 | Reliant Technologies, Inc. | Method and apparatus for monitoring and controlling thermally induced tissue treatment |
US8203132B2 (en) | 2005-09-08 | 2012-06-19 | Carestream Health, Inc. | Apparatus and method for imaging ionizing radiation |
US8041409B2 (en) | 2005-09-08 | 2011-10-18 | Carestream Health, Inc. | Method and apparatus for multi-modal imaging |
US20090086908A1 (en) * | 2005-09-08 | 2009-04-02 | John William Harder | Apparatus and method for multi-modal imaging using nanoparticle multi-modal imaging probes |
US20100220836A1 (en) | 2005-09-08 | 2010-09-02 | Feke Gilbert D | Apparatus and method for multi-modal imaging |
US8050735B2 (en) | 2005-09-08 | 2011-11-01 | Carestream Health, Inc. | Apparatus and method for multi-modal imaging |
US8660631B2 (en) | 2005-09-08 | 2014-02-25 | Bruker Biospin Corporation | Torsional support apparatus and method for craniocaudal rotation of animals |
US7622723B2 (en) * | 2005-09-23 | 2009-11-24 | Veritide Limited | System for spore detection |
WO2007067999A2 (en) | 2005-12-09 | 2007-06-14 | Amnis Corporation | Extended depth of field imaging for high speed object analysis |
WO2007075565A2 (en) | 2005-12-16 | 2007-07-05 | Shachaf Catherine M | Diagnostic system for the detection and diagnosis of skin cancer |
WO2007084981A2 (en) * | 2006-01-19 | 2007-07-26 | The Regents Of The University Of Michigan | System and method for photoacoustic imaging and monitoring of laser therapy |
WO2008030113A1 (en) * | 2006-09-05 | 2008-03-13 | Veritide Limited | Method for detection or identification of bacteria or bacterial spores |
WO2008067438A2 (en) * | 2006-11-29 | 2008-06-05 | The Regents Of University Of Michigan | System and method for photoacoustic guided diffuse optical imaging |
US20080188007A1 (en) * | 2007-02-06 | 2008-08-07 | Meridian Life Science, Inc. | Fluorescent single chain antibody and its use in detection of analytes |
US8825137B2 (en) * | 2007-03-09 | 2014-09-02 | Xiaodong Wu | Repositionable gynecological applicator for image-guided radiosurgery (IGRS) and image-guided radiation therapy (IGRT) for localized treatment of gynecological tumors |
WO2009026313A1 (en) * | 2007-08-20 | 2009-02-26 | Colorado Seminary, Which Owns And Operates The University Of Denver | Photoinduced signal amplification through externally sensitized photofragmentation in masked photosensitizers and photoamplified fluorescence turn-off system |
EP2197546A1 (en) * | 2007-09-14 | 2010-06-23 | Light Sciences Oncology, Inc. | Systems, devices, and methods for photoactive assisted resection |
ATE546174T1 (de) | 2008-01-08 | 2012-03-15 | Bluesky Medical Group Inc | Ununterbrochene variable unterdruckwundbehandlung und steuerungsverfahren dafür |
US8509880B1 (en) * | 2008-02-06 | 2013-08-13 | Remicalm, Llc | Handheld portable examination device for diagnostic use |
EP2257320A2 (en) | 2008-03-12 | 2010-12-08 | Bluesky Medical Group Inc. | Negative pressure dressing and method of using same |
EP2274051A4 (en) * | 2008-05-09 | 2011-07-20 | Hugh Beckman | MEDICAL DEVICE FOR USE IN THE DIAGNOSIS AND TREATMENT OF TISSUE ANOMALIES AND METHOD FOR THE IMPLEMENTATION |
EP3501384A3 (en) | 2008-05-20 | 2019-10-16 | University Health Network | Method for fluorescence-based imaging and monitoring |
WO2010008483A1 (en) * | 2008-06-25 | 2010-01-21 | Bioptigen, Inc. | Volume phase grating spectrometers and related methods and systems |
JP5380026B2 (ja) * | 2008-09-24 | 2014-01-08 | シスメックス株式会社 | 標本撮像装置 |
CN104155210B (zh) | 2008-10-02 | 2017-08-22 | 彼克斯赛尔医疗科技有限公司 | 基于粘弹性聚焦的光学成像 |
US9788728B2 (en) * | 2009-01-23 | 2017-10-17 | Beth Israel Deaconess Medical Center, Inc. | Endoscopic polarized multispectral light scattering scanning method |
US20120029348A1 (en) * | 2009-04-14 | 2012-02-02 | The Gemeral Hospital Corporation | Method and apparatus for multimodal imaging of biological tissue |
EP2473102B1 (en) * | 2009-09-04 | 2018-05-23 | The Johns Hopkins University | Multimodal laser speckle imaging |
US8451524B2 (en) | 2009-09-29 | 2013-05-28 | Amnis Corporation | Modifying the output of a laser to achieve a flat top in the laser's Gaussian beam intensity profile |
US8817115B1 (en) | 2010-05-05 | 2014-08-26 | Amnis Corporation | Spatial alignment of image data from a multichannel detector using a reference image |
CN102262077A (zh) * | 2010-05-26 | 2011-11-30 | 电子科技大学 | 一种锐化的癌症早期诊断和治疗效果检查的装置 |
DE202011001569U1 (de) * | 2011-01-14 | 2012-03-01 | Berthold Technologies Gmbh & Co. Kg | Vorrichtung zur Messung von optischen Eigenschaften in Mikroplatten |
US20130324846A1 (en) * | 2011-02-17 | 2013-12-05 | University Of Massachusetts | Devices and methods for optical pathology |
WO2013029082A1 (en) * | 2011-09-02 | 2013-03-07 | Ttaas Thommo's Training & Assessment Systems Pty Ltd | Method for detecting fluid injection in a patient |
JP5926806B2 (ja) | 2011-09-22 | 2016-05-25 | ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity | アブレーションされた組織を視覚化するシステムと方法 |
ES2727868T3 (es) | 2011-09-22 | 2019-10-21 | Univ George Washington | Sistemas para visualizar el tejido ablacionado |
US11433147B2 (en) | 2014-02-10 | 2022-09-06 | Quaker Chemical (Australasia) Pty Ltd | Fluorescent fluid for detecting fluid injection |
JP5900000B2 (ja) * | 2012-02-16 | 2016-04-06 | 富士通株式会社 | 樹脂硬化状態モニタリング装置及び樹脂硬化状態モニタリング方法 |
KR20160037834A (ko) * | 2013-03-14 | 2016-04-06 | 루미셀, 아이엔씨. | 의료 이미징 장치 및 사용 방법 |
DK2997353T3 (da) * | 2013-05-15 | 2023-01-16 | The Administrators Of The Tulane Educational Fund | Mikroskopi af en vævsprøve under anvendelse af struktureret belysning |
US10182757B2 (en) * | 2013-07-22 | 2019-01-22 | The Rockefeller University | System and method for optical detection of skin disease |
RU2678080C2 (ru) * | 2013-09-24 | 2019-01-22 | Конинклейке Филипс Н.В. | Способ вычисления плана хирургической операции |
WO2015077474A1 (en) | 2013-11-20 | 2015-05-28 | The George Washington University | Systems and methods for hyperspectral analysis of cardiac tissue |
ES2894912T3 (es) | 2014-07-24 | 2022-02-16 | Univ Health Network | Recopilación y análisis de datos con fines de diagnóstico |
JP6453607B2 (ja) * | 2014-10-15 | 2019-01-16 | デジタルワン株式会社 | 口腔内検診管理システム |
US10143517B2 (en) | 2014-11-03 | 2018-12-04 | LuxCath, LLC | Systems and methods for assessment of contact quality |
CN113143440A (zh) | 2014-11-03 | 2021-07-23 | 乔治华盛顿大学 | 用于损伤评估的系统和方法 |
US10779904B2 (en) | 2015-07-19 | 2020-09-22 | 460Medical, Inc. | Systems and methods for lesion formation and assessment |
WO2017027881A1 (en) | 2015-08-13 | 2017-02-16 | The Rockefeller University | Quantitative dermoscopic melanoma screening |
EP3454918A1 (en) | 2016-05-13 | 2019-03-20 | Smith & Nephew PLC | Sensor enabled wound monitoring and therapy apparatus |
US10568695B2 (en) * | 2016-09-26 | 2020-02-25 | International Business Machines Corporation | Surgical skin lesion removal |
US11690570B2 (en) | 2017-03-09 | 2023-07-04 | Smith & Nephew Plc | Wound dressing, patch member and method of sensing one or more wound parameters |
EP3592230A1 (en) | 2017-03-09 | 2020-01-15 | Smith & Nephew PLC | Apparatus and method for imaging blood in a target region of tissue |
US11627908B2 (en) * | 2017-03-31 | 2023-04-18 | University Of Massachusetts | Instruments and methods for imaging collagen structure in vivo |
CA3059516A1 (en) | 2017-04-11 | 2018-10-18 | Smith & Nephew Plc | Component positioning and stress relief for sensor enabled wound dressings |
AU2018269112B2 (en) | 2017-05-15 | 2024-05-02 | Smith & Nephew Plc | Wound analysis device and method |
CA3066073A1 (en) | 2017-06-23 | 2018-12-27 | Smith & Nephew Plc | Positioning of sensors for sensor enabled wound monitoring or therapy |
GB201809007D0 (en) | 2018-06-01 | 2018-07-18 | Smith & Nephew | Restriction of sensor-monitored region for sensor-enabled wound dressings |
GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
AU2018312883A1 (en) | 2017-08-10 | 2020-02-20 | Smith & Nephew Plc | Positioning of sensors for sensor enabled wound monitoring or therapy |
WO2019048624A1 (en) | 2017-09-10 | 2019-03-14 | Smith & Nephew Plc | ENCAPSULATION INSPECTION SYSTEMS AND METHODS AND COMPONENTS IN SENSOR EQUIPMENT DRESSINGS |
GB201718870D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew Inc | Sensor enabled wound therapy dressings and systems |
GB201804971D0 (en) | 2018-03-28 | 2018-05-09 | Smith & Nephew | Electrostatic discharge protection for sensors in wound therapy |
GB201718859D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew | Sensor positioning for sensor enabled wound therapy dressings and systems |
JP7282079B2 (ja) | 2017-09-27 | 2023-05-26 | スミス アンド ネフュー ピーエルシー | センサが使用可能な陰圧創傷監視および療法装置のph感知 |
EP3687396A1 (en) | 2017-09-28 | 2020-08-05 | Smith & Nephew plc | Neurostimulation and monitoring using sensor enabled wound monitoring and therapy apparatus |
EP3709943A1 (en) | 2017-11-15 | 2020-09-23 | Smith & Nephew PLC | Integrated sensor enabled wound monitoring and/or therapy dressings and systems |
CN110346291A (zh) * | 2018-04-03 | 2019-10-18 | 锐准医光股份有限公司 | 一种生物样本的影像合成方法及采用该方法的光学系统 |
WO2019245946A1 (en) * | 2018-06-18 | 2019-12-26 | Calico Life Sciences Llc | System and method for inferring protein binding |
US11944418B2 (en) | 2018-09-12 | 2024-04-02 | Smith & Nephew Plc | Device, apparatus and method of determining skin perfusion pressure |
GB201820927D0 (en) | 2018-12-21 | 2019-02-06 | Smith & Nephew | Wound therapy systems and methods with supercapacitors |
US10613012B1 (en) * | 2019-10-17 | 2020-04-07 | Horiba Instruments Incorporated | Apparatus and method for observation of microscopic movements and counting of particles in colloids |
KR102116232B1 (ko) * | 2019-11-12 | 2020-05-28 | (주)로고스바이오시스템스 | 시료 검출 장치 및 이를 이용한 시료 검출 방법 |
KR20230048426A (ko) * | 2020-09-29 | 2023-04-11 | 로레알 | 다양한 화장품층을 갖는 피부 상의 선스크린을 검출하기 위한 방법 및 장치 |
FR3115602A1 (fr) * | 2020-10-22 | 2022-04-29 | L'oreal | Procede et appareil de detection d’ecran solaire sur de la peau ayant diverses couches de produit cosmetique |
WO2022128756A1 (de) | 2020-12-16 | 2022-06-23 | Tomas Pink | Verfahren zur erkennung von adsorptionsunterschieden, anlagerungs- und/oder rückhaltbereichen in teilweise lichtdurchlässigen behältnissen |
EP4016056A1 (de) | 2020-12-16 | 2022-06-22 | Tomas Pink | Verfahren zur erkennung von adsorptionsunterschieden, anlagerungs- und/oder rückhaltebereichen in teilweise lichtdurchlässigen behältnissen |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535027A (ja) * | 1999-01-25 | 2002-10-22 | マサチユセツツ・インスチチユート・オブ・テクノロジイ | 組織の偏光散乱分光法 |
JP2002535645A (ja) * | 1999-01-25 | 2002-10-22 | ニユートン・ラボラトリーズ・インコーポレーテツド | 偏光を使用する組織の画像形成 |
JP2003510112A (ja) * | 1999-09-23 | 2003-03-18 | ジー.ナドウ リチャード | 直交偏光スペクトルイメージングの医学的応用 |
JP2003527916A (ja) * | 2000-03-28 | 2003-09-24 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 診断用マルチスペクトルデジタル画像化のための方法および装置 |
JP2005515473A (ja) * | 2002-01-18 | 2005-05-26 | ニユートン・ラボラトリーズ・インコーポレーテツド | 分光診断方法とシステム |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5913697B2 (ja) | 1977-04-01 | 1984-03-31 | オリンパス光学工業株式会社 | 螢光偏光測光顕微鏡によるガン診断装置 |
US4541438A (en) * | 1983-06-02 | 1985-09-17 | The Johns Hopkins University | Localization of cancerous tissue by monitoring infrared fluorescence emitted by intravenously injected porphyrin tumor-specific markers excited by long wavelength light |
US5042494A (en) * | 1985-11-13 | 1991-08-27 | Alfano Robert R | Method and apparatus for detecting cancerous tissue using luminescence excitation spectra |
JPS62247232A (ja) * | 1986-04-21 | 1987-10-28 | Agency Of Ind Science & Technol | 蛍光測定装置 |
US5270788A (en) * | 1986-05-27 | 1993-12-14 | Boris Cercek | Apparatus for measuring polarization of bathochromically shifted fluorescence |
US5205291A (en) * | 1988-11-08 | 1993-04-27 | Health Research, Inc. | In vivo fluorescence photometer |
SE8900612D0 (sv) * | 1989-02-22 | 1989-02-22 | Jonas Johansson | Vaevnadskarakterisering utnyttjande ett blodfritt fluorescenskriterium |
US5079262A (en) * | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
ATE147647T1 (de) * | 1989-11-20 | 1997-02-15 | Hamamatsu Photonics Kk | Mit einem laserstrahlengenerator versehene einrichtung für die diagnose und behandlung von krebs |
US5131398A (en) * | 1990-01-22 | 1992-07-21 | Mediscience Technology Corp. | Method and apparatus for distinguishing cancerous tissue from benign tumor tissue, benign tissue or normal tissue using native fluorescence |
DE4026821A1 (de) * | 1990-08-24 | 1992-03-05 | Philips Patentverwaltung | Verfahren zur erfassung von anomalien der haut, insbesondere von melanomen, sowie vorrichtung zur durchfuehrung des verfahrens |
US6258530B1 (en) * | 1990-09-28 | 2001-07-10 | Ixsys, Inc. | Surface expression libraries of randomized peptides |
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
GB2254417A (en) | 1991-04-05 | 1992-10-07 | Bijan Jouza | Photodynamic laser detection for cancer diagnosis |
SE9103837L (sv) | 1991-12-21 | 1993-06-22 | Jonas Johansson | Fluorescensdiagnostik av cancer utnyttjande delta- aminolevulinsyra |
US5413108A (en) * | 1993-04-21 | 1995-05-09 | The Research Foundation Of City College Of New York | Method and apparatus for mapping a tissue sample for and distinguishing different regions thereof based on luminescence measurements of cancer-indicative native fluorophor |
US5364922A (en) * | 1993-09-07 | 1994-11-15 | Dow Corning Corporation | Curable compositions containing an anaerobically inactive hydrosilation catalyst and method for preparing said compositions |
US5579773A (en) * | 1994-09-30 | 1996-12-03 | Martin Marietta Energy Systems, Inc. | Laser-induced differential normalized fluorescence method for cancer diagnosis |
AT403654B (de) * | 1994-12-01 | 1998-04-27 | Binder Michael Dr | Einrichtung zur optischen untersuchung von human-haut sowie derselben zugeordnete auswertungs-einrichtung |
US6258576B1 (en) | 1996-06-19 | 2001-07-10 | Board Of Regents, The University Of Texas System | Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy |
FR2737845B1 (fr) | 1995-08-16 | 1998-01-02 | Centre Nat Rech Scient | Dispositif d'imagerie endoscopique pour la detection precoce de lesions superficielles cancereuses ou precancereuses |
US20040052730A1 (en) * | 1995-10-04 | 2004-03-18 | Cytoscan Sciences, L.L.C. | Methods and systems for assessing biological materials using optical and spectroscopic detection techniques |
GB9521784D0 (en) * | 1995-10-24 | 1996-01-03 | Rosslyn Medical Ltd | Diagnostic apparatus |
US5929443A (en) * | 1995-12-18 | 1999-07-27 | The Research Foundation City College Of New York | Imaging of objects based upon the polarization or depolarization of light |
US5647368A (en) * | 1996-02-28 | 1997-07-15 | Xillix Technologies Corp. | Imaging system for detecting diseased tissue using native fluorsecence in the gastrointestinal and respiratory tract |
US6135965A (en) * | 1996-12-02 | 2000-10-24 | Board Of Regents, The University Of Texas System | Spectroscopic detection of cervical pre-cancer using radial basis function networks |
US6091983A (en) * | 1997-02-07 | 2000-07-18 | Alfano; Robert R. | Imaging of objects in turbid media based upon the preservation of polarized luminescence emitted from contrast agents |
US6317624B1 (en) * | 1997-05-05 | 2001-11-13 | The General Hospital Corporation | Apparatus and method for demarcating tumors |
US6083487A (en) * | 1997-08-25 | 2000-07-04 | Advanced Photodynamic Technologies, Inc. | Methylene blue and toluidene blue mediated fluorescence diagnosis of cancer |
US6070093A (en) * | 1997-12-02 | 2000-05-30 | Abbott Laboratories | Multiplex sensor and method of use |
US6055451A (en) * | 1997-12-12 | 2000-04-25 | Spectrx, Inc. | Apparatus and method for determining tissue characteristics |
US6091985A (en) * | 1998-01-23 | 2000-07-18 | Research Foundation Of City College Of New York | Detection of cancer and precancerous conditions in tissues and/or cells using native fluorescence excitation spectroscopy |
US6590651B1 (en) * | 1998-05-19 | 2003-07-08 | Spectrx, Inc. | Apparatus and method for determining tissue characteristics |
US6256530B1 (en) | 1998-09-15 | 2001-07-03 | Denvu, L.L.C. | Optical instrument and technique for cancer diagnosis using in-vivo fluorescence emission of test tissue |
US6352502B1 (en) * | 1998-12-03 | 2002-03-05 | Lightouch Medical, Inc. | Methods for obtaining enhanced spectroscopic information from living tissue, noninvasive assessment of skin condition and detection of skin abnormalities |
US6665556B1 (en) * | 1999-01-29 | 2003-12-16 | Robert R. Alfano | Method and apparatus for examining a tissue using the spectral wing emission therefrom induced by visible to infrared photoexcitation |
US20030026762A1 (en) * | 1999-05-05 | 2003-02-06 | Malmros Mark K. | Bio-spectral imaging system and methods for diagnosing cell disease state |
US6175759B1 (en) * | 1999-06-28 | 2001-01-16 | The United States Of America As Represented By The Secretary Of The Air Force | Contrast agent for multispectral infrared transillumination and fluorescence of turbid media |
US6587711B1 (en) * | 1999-07-22 | 2003-07-01 | The Research Foundation Of Cuny | Spectral polarizing tomographic dermatoscope |
GR1004180B (el) * | 2000-03-28 | 2003-03-11 | ����������� ����� ��������� (����) | Μεθοδος και συστημα χαρακτηρισμου και χαρτογραφησης αλλοιωσεων των ιστων |
US6678398B2 (en) * | 2000-09-18 | 2004-01-13 | Sti Medical Systems, Inc. | Dual mode real-time screening and rapid full-area, selective-spectral, remote imaging and analysis device and process |
US6674527B2 (en) * | 2001-02-27 | 2004-01-06 | Cambridge Research & Instrumentation Inc. | Ratiometric background correction for fluorescence polarization assays |
US7257437B2 (en) * | 2002-07-05 | 2007-08-14 | The Regents Of The University Of California | Autofluorescence detection and imaging of bladder cancer realized through a cystoscope |
US7016717B2 (en) * | 2002-07-05 | 2006-03-21 | The Regents Of The University Of California | Near-infrared spectroscopic tissue imaging for medical applications |
WO2004073501A2 (en) * | 2003-02-20 | 2004-09-02 | Gutin Mikhail | Optical coherence tomography with 3d coherence scanning |
EP1610671B1 (en) * | 2003-03-18 | 2013-08-21 | The General Hospital Corporation | Polarized light devices and methods |
JP2008528064A (ja) | 2005-01-21 | 2008-07-31 | パーセプトロニクス メディカル インク | 内視鏡画像法の間に得られた反射率スペクトル測定から癌変化を測定する方法と装置 |
-
2004
- 2004-09-20 JP JP2006527087A patent/JP4700001B2/ja not_active Expired - Fee Related
- 2004-09-20 AU AU2004273992A patent/AU2004273992B2/en not_active Ceased
- 2004-09-20 US US10/945,239 patent/US7289205B2/en not_active Expired - Fee Related
- 2004-09-20 WO PCT/US2004/030623 patent/WO2005027730A2/en active Application Filing
- 2004-09-20 EP EP04784476A patent/EP1670347A4/en not_active Withdrawn
- 2004-09-20 CA CA002539184A patent/CA2539184A1/en not_active Abandoned
-
2006
- 2006-03-16 IL IL174379A patent/IL174379A0/en unknown
-
2007
- 2007-10-04 US US11/906,863 patent/US7564550B2/en not_active Expired - Fee Related
-
2009
- 2009-07-21 US US12/460,596 patent/US8139211B2/en not_active Expired - Fee Related
-
2012
- 2012-01-13 US US13/350,549 patent/US20120170037A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535027A (ja) * | 1999-01-25 | 2002-10-22 | マサチユセツツ・インスチチユート・オブ・テクノロジイ | 組織の偏光散乱分光法 |
JP2002535645A (ja) * | 1999-01-25 | 2002-10-22 | ニユートン・ラボラトリーズ・インコーポレーテツド | 偏光を使用する組織の画像形成 |
JP2003510112A (ja) * | 1999-09-23 | 2003-03-18 | ジー.ナドウ リチャード | 直交偏光スペクトルイメージングの医学的応用 |
JP2003527916A (ja) * | 2000-03-28 | 2003-09-24 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 診断用マルチスペクトルデジタル画像化のための方法および装置 |
JP2005515473A (ja) * | 2002-01-18 | 2005-05-26 | ニユートン・ラボラトリーズ・インコーポレーテツド | 分光診断方法とシステム |
Also Published As
Publication number | Publication date |
---|---|
EP1670347A2 (en) | 2006-06-21 |
US7564550B2 (en) | 2009-07-21 |
IL174379A0 (en) | 2006-08-01 |
WO2005027730A3 (en) | 2007-01-04 |
US20050094147A1 (en) | 2005-05-05 |
EP1670347A4 (en) | 2011-05-18 |
US8139211B2 (en) | 2012-03-20 |
US20100053607A1 (en) | 2010-03-04 |
US7289205B2 (en) | 2007-10-30 |
US20080030732A1 (en) | 2008-02-07 |
AU2004273992A1 (en) | 2005-03-31 |
US20120170037A1 (en) | 2012-07-05 |
CA2539184A1 (en) | 2005-03-31 |
WO2005027730A2 (en) | 2005-03-31 |
JP2007511243A (ja) | 2007-05-10 |
AU2004273992B2 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4700001B2 (ja) | 蛍光偏極撮像方法 | |
US7627363B2 (en) | Polarized light imaging devices and methods | |
Wagnieres et al. | In vivo fluorescence spectroscopy and imaging for oncological applications | |
Ramanujam | Fluorescence spectroscopy in vivo | |
Yang et al. | A multispectral fluorescence imaging system: Design and initial clinical tests in intra‐operative Photofrin‐photodynamic therapy of brain tumors | |
Dacosta et al. | New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions | |
AU716504B2 (en) | Method for improved selectivity in photo-activation and detection of molecular diagnostic agents | |
Banerjee et al. | Emission spectra of colonic tissue and endogenous fluorophores | |
Abramczyk et al. | Oncologic photodynamic diagnosis and therapy: confocal Raman/fluorescence imaging of metal phthalocyanines in human breast cancer tissue in vitro | |
Eker et al. | Multivariate analysis of laryngeal fluorescence spectra recorded in vivo | |
Vo-Dinh | Fluorescence spectroscopy for biomedical diagnostics | |
Hegyi et al. | New developments in fluorescence diagnostics | |
Chaudhury et al. | Oncologic applications of biophotonics: prospects and problems | |
Braichotte et al. | Clinical comparison of the pharmacokinetics of m-THPC and Photofrin II as observed by light-induced fluorescence | |
Johansson | Fluorescence spectroscopy for medical and environmental diagnostics | |
Chorvatova et al. | Oncology applications: Optical diagnostics of cancer | |
Al-Thunayan | Cancer diagnosis by synchronous fluorescence spectra of blood and urine components | |
Mathurb | Optical diagnostic and therapeutic technologies in pulmonary medicine | |
Delgado et al. | Ex‐vivo autofluorescence measurements of human tissues | |
Tagg et al. | Biophotonic and other physical methods for characterizing oral mucosa | |
Pandey et al. | Utility of tumor-avid photosensitizers in developing bifunctional agents for tumor imaging and/or phototherapy | |
Meerovich et al. | Laser fluorescent system for endoscopic tumor diagnostic and irradiation control in photodynamic therapy | |
Meerovich et al. | Laser fluorescent system for endoscopic tumor diagnostic and irradiation control in photodynamic therapy | |
Ericson et al. | Imaging of photosensitizers in skin | |
Deckelbaum | Laser-induced arterial fluorescence spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100915 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101015 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101109 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110303 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |